-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, June 25, 2021 is about halfway through, and the performance of listed companies in the first half of the year has gradually surfaced
.
According to statistics, 42 pharmaceutical companies in A-shares have disclosed their performance in the first half of 2021
.
Among them, Kelun Pharmaceutical, Harbin Sanlian, SINBON Pharmaceuticals, and Zuoli Pharmaceuticals are expected to double their net profits.
Daan Gene's net profit will exceed 1.
6 billion yuan.
Harbin Sanlian has the largest increase, with a year-on-year increase of 1856.
54% to 1927.
68%.
; 4 companies are expected to turn losses into profits, Can Sino will usher in the first profit, the current market value of more than 160 billion yuan
.
In addition, 14 companies are expected to lose money, and as many as 11 companies continue to lose money.
Innovative Medical has accumulated losses of nearly 1.
5 billion yuan in the past two years and is expected to continue to lose money in the first half of this year
.
.
According to statistics, 42 pharmaceutical companies in A-shares have disclosed their performance in the first half of 2021
.
Among them, Kelun Pharmaceutical, Harbin Sanlian, SINBON Pharmaceuticals, and Zuoli Pharmaceuticals are expected to double their net profits.
Daan Gene's net profit will exceed 1.
6 billion yuan.
Harbin Sanlian has the largest increase, with a year-on-year increase of 1856.
54% to 1927.
68%.
; 4 companies are expected to turn losses into profits, Can Sino will usher in the first profit, the current market value of more than 160 billion yuan
.
In addition, 14 companies are expected to lose money, and as many as 11 companies continue to lose money.
Innovative Medical has accumulated losses of nearly 1.
5 billion yuan in the past two years and is expected to continue to lose money in the first half of this year
.
A-share pharmaceutical companies that have disclosed their performance forecast for the first half of 2021
Kelun, SINBON.
.
.
11 net profits doubled! This "Hurricane" over 1.
6 billion is too amazing
.
.
11 net profits doubled! This "Hurricane" over 1.
6 billion is too amazing
On the whole, more than 20 pharmaceutical companies reported good news.
Among them, Daan Gene's net profit exceeded 1.
6 billion yuan, and 11 companies including Kelun Pharmaceutical, Harbin Sanlian, Xinbang Pharmaceutical, and Zuoli Pharmaceutical were expected to double their net profits.
The Harbin Sanlian had the largest increase, with a year-on-year increase of 1856.
54% to 1927.
68%
.
Among them, Daan Gene's net profit exceeded 1.
6 billion yuan, and 11 companies including Kelun Pharmaceutical, Harbin Sanlian, Xinbang Pharmaceutical, and Zuoli Pharmaceutical were expected to double their net profits.
The Harbin Sanlian had the largest increase, with a year-on-year increase of 1856.
54% to 1927.
68%
.
Kelun Pharmaceutical: The company's performance in the first quarter of this year has grown rapidly, with net profit increasing by more than 700% year-on-year.
Net profit in the first half of the year is expected to be 400 million to 500 million yuan
.
Regarding the rapid growth of performance, Kelun Pharmaceutical said that on the one hand, with the effective control of the domestic epidemic in the first half of 2021, production and sales gradually recovered, and sales of the company’s traditional infusion, non-infusion products and new products increased year-on-year; on the other hand, Yili Chuanning Affected by the market environment, prices of biological products have resumed rising, and profits have increased year-on-year
.
In addition, the company continued to increase investment in innovation, and R&D expenses increased year-on-year
.
Recently, Kelun Pharmaceutical has received frequent reports.
The KL590586 capsule, a type 1 innovative drug developed by its holding subsidiary Sichuan Kelun Botai Biopharmaceutical, has been notified of clinical trials; Hunan Kelun Pharmaceutical’s linezolid glucose injection has been approved and reviewed.
Won admission tickets for 1 billion injections from China
.
In addition, Kelun Pharmaceutical intends to spin off its holding subsidiary Yili Chuanning Biotechnology to be listed on the Shenzhen Stock Exchange's Growth Enterprise Market
.
On June 22, Kelun Pharmaceutical once again issued two announcements.
Hunan Kelun Pharmaceutical’s erlotinib hydrochloride and Shandong Kelun Pharmaceutical’s iopamidol injection were approved, and the iopamidol injection was Kelun.
The first drug approved to enter the field of diagnostic imaging
.
Net profit in the first half of the year is expected to be 400 million to 500 million yuan
.
Regarding the rapid growth of performance, Kelun Pharmaceutical said that on the one hand, with the effective control of the domestic epidemic in the first half of 2021, production and sales gradually recovered, and sales of the company’s traditional infusion, non-infusion products and new products increased year-on-year; on the other hand, Yili Chuanning Affected by the market environment, prices of biological products have resumed rising, and profits have increased year-on-year
.
In addition, the company continued to increase investment in innovation, and R&D expenses increased year-on-year
.
Recently, Kelun Pharmaceutical has received frequent reports.
The KL590586 capsule, a type 1 innovative drug developed by its holding subsidiary Sichuan Kelun Botai Biopharmaceutical, has been notified of clinical trials; Hunan Kelun Pharmaceutical’s linezolid glucose injection has been approved and reviewed.
Won admission tickets for 1 billion injections from China
.
In addition, Kelun Pharmaceutical intends to spin off its holding subsidiary Yili Chuanning Biotechnology to be listed on the Shenzhen Stock Exchange's Growth Enterprise Market
.
On June 22, Kelun Pharmaceutical once again issued two announcements.
Hunan Kelun Pharmaceutical’s erlotinib hydrochloride and Shandong Kelun Pharmaceutical’s iopamidol injection were approved, and the iopamidol injection was Kelun.
The first drug approved to enter the field of diagnostic imaging
.
SINBON Pharmaceuticals: The net profit for the first half of the year is estimated to be 139 million to 157 million yuan, a year-on-year increase of 290% to 340.
02%, which is close to the full-year level of 2020
.
In this regard, SINBON Pharmaceuticals stated that the impact of the new crown epidemic in 2020 will have a greater impact on the company's operating performance in the first quarter, and it will return to normal in the second quarter.
In the first half of 2021, all business sectors of the company will maintain a continuous growth trend
.
02%, which is close to the full-year level of 2020
.
In this regard, SINBON Pharmaceuticals stated that the impact of the new crown epidemic in 2020 will have a greater impact on the company's operating performance in the first quarter, and it will return to normal in the second quarter.
In the first half of 2021, all business sectors of the company will maintain a continuous growth trend
.
Daan Gene: After making a huge profit of more than 2 billion yuan last year, the company's net profit in the first quarter of this year has exceeded 1 billion yuan.
The growth in the first half of this year is still amazing.
The net profit is expected to be 1.
35 billion to 1.
65 billion yuan, an increase of 73.
41% to 111.
95.
%
.
It is worth mentioning that the net profit in the first half of 2020 exceeded 700 million yuan, a year-on-year increase of 118.
65%; in the first half of 2019, it was only 60.
51 million yuan
.
Daan Gene said that the rapid growth in performance is mainly due to the impact of the new crown virus, and the market has a large demand for new crown virus nucleic acid detection reagents
.
In early June of this year, Daan Gene issued an announcement stating that the company name "Sun Yat-Sen University Daan Gene Co.
, Ltd.
" was changed to "Guangzhou Daan Gene Co.
, Ltd.
" due to a change in the actual controller
.
According to the data, according to the latest business registration information of the controlling shareholder Guangzhou Zhongda Holding Co.
, Ltd.
, its shareholder was changed from "Sun Yat-Sen University" to "Guangzhou Financial Holding Group Co.
, Ltd.
", and the actual controller of the company was changed from "Sun Yat-Sen University" to "Guangzhou City".
People's Government"
.
The growth in the first half of this year is still amazing.
The net profit is expected to be 1.
35 billion to 1.
65 billion yuan, an increase of 73.
41% to 111.
95.
%
.
It is worth mentioning that the net profit in the first half of 2020 exceeded 700 million yuan, a year-on-year increase of 118.
65%; in the first half of 2019, it was only 60.
51 million yuan
.
Daan Gene said that the rapid growth in performance is mainly due to the impact of the new crown virus, and the market has a large demand for new crown virus nucleic acid detection reagents
.
In early June of this year, Daan Gene issued an announcement stating that the company name "Sun Yat-Sen University Daan Gene Co.
, Ltd.
" was changed to "Guangzhou Daan Gene Co.
, Ltd.
" due to a change in the actual controller
.
According to the data, according to the latest business registration information of the controlling shareholder Guangzhou Zhongda Holding Co.
, Ltd.
, its shareholder was changed from "Sun Yat-Sen University" to "Guangzhou Financial Holding Group Co.
, Ltd.
", and the actual controller of the company was changed from "Sun Yat-Sen University" to "Guangzhou City".
People's Government"
.
14 companies lose money! 4 companies turned losses, 100 billion market capitalization pharmaceutical companies will welcome the first profit
According to statistics, four companies, including Cansino and Toujing Life, are expected to turn losses into profits.
Among them, Cansino may make profits for the first time, and its current market value exceeds 160 billion yuan
.
In addition, 14 pharmaceutical companies lost money, while 11 continued to lose money.
Among them, Innovative Medical continued to lose money in the first half of this year after a cumulative loss of nearly 1.
5 billion from 2019 to 2020
.
Among them, Cansino may make profits for the first time, and its current market value exceeds 160 billion yuan
.
In addition, 14 pharmaceutical companies lost money, while 11 continued to lose money.
Among them, Innovative Medical continued to lose money in the first half of this year after a cumulative loss of nearly 1.
5 billion from 2019 to 2020
.
Cansino: In August 2020, Cansino officially listed on the A-share science and technology innovation board.
The company is an innovative vaccine company dedicated to R&D, production and commercialization that meets Chinese and international standards
.
Cansino disclosed the first half of the performance forecast in the first quarter of 2021.
The company expects to turn losses into profits, and this will be the first time Cansino has achieved profitability
.
According to data, from 2016 to 2020, the company is in a state of loss, with a cumulative loss of more than 800 million yuan
.
Kansino stated that the main reason for the turnaround is that the recombinant new coronavirus vaccine (type 5 adenovirus vector) has obtained emergency use authorization from Mexico, Pakistan and other countries and the approval of conditional listing in China, which has positively generated the company's main business income.
Influence
.
Recently, Ecuador’s National Health Regulatory Agency announced that it has approved Cansino’s new crown vaccine for use in Ecuador.
This is the second Chinese new crown vaccine approved for use in Ecuador after Coxing’s new crown vaccine.
In addition, the Malaysian Ministry of Health announced , The Malaysian Drug Control Law Enforcement Group meeting decided to conditionally approve two single-dose vaccines, including China's Cansino vaccine and Johnson & Johnson vaccine for use in Malaysia
.
Currently, Cansino has a market value of more than 160 billion yuan
.
The company is an innovative vaccine company dedicated to R&D, production and commercialization that meets Chinese and international standards
.
Cansino disclosed the first half of the performance forecast in the first quarter of 2021.
The company expects to turn losses into profits, and this will be the first time Cansino has achieved profitability
.
According to data, from 2016 to 2020, the company is in a state of loss, with a cumulative loss of more than 800 million yuan
.
Kansino stated that the main reason for the turnaround is that the recombinant new coronavirus vaccine (type 5 adenovirus vector) has obtained emergency use authorization from Mexico, Pakistan and other countries and the approval of conditional listing in China, which has positively generated the company's main business income.
Influence
.
Recently, Ecuador’s National Health Regulatory Agency announced that it has approved Cansino’s new crown vaccine for use in Ecuador.
This is the second Chinese new crown vaccine approved for use in Ecuador after Coxing’s new crown vaccine.
In addition, the Malaysian Ministry of Health announced , The Malaysian Drug Control Law Enforcement Group meeting decided to conditionally approve two single-dose vaccines, including China's Cansino vaccine and Johnson & Johnson vaccine for use in Malaysia
.
Currently, Cansino has a market value of more than 160 billion yuan
.
Innovative Medical: Innovative Medical’s main business is medical services, and it has three wholly-owned hospital subsidiaries, Jianhua Hospital , Kanghua Hospital and Futian Hospital
.
The company has a cumulative loss of nearly 1.
5 billion yuan from 2019 to 2020, and it is expected to lose 55 million to 45 million yuan in the first half of this year
.
Regarding the decline in performance, Innovative Medical said that in the first quarter of 2021, the net profit loss was 24.
05 million yuan.
The following hospitals did not experience major changes in the operating situation in the second quarter.
The company expects to continue to lose money in the first half of 2021
.
In early June, the Shenzhen Stock Exchange issued an inquiry letter for the 2020 annual report to Innovative Medical, requesting explanations on the company’s provision of estimated liabilities and the reasons and rationality of the impairment of goodwill; on June 18, Innovative Medical issued an inquiry.
The inquiry letter responded to the announcement, and then the Shenzhen Stock Exchange issued a second inquiry letter for the 2020 annual report to Innovative Medical
.
During this period, Innovative Medical announced that the company used its own funds to increase the capital of Futian Hospital by 10 million yuan
.
.
The company has a cumulative loss of nearly 1.
5 billion yuan from 2019 to 2020, and it is expected to lose 55 million to 45 million yuan in the first half of this year
.
Regarding the decline in performance, Innovative Medical said that in the first quarter of 2021, the net profit loss was 24.
05 million yuan.
The following hospitals did not experience major changes in the operating situation in the second quarter.
The company expects to continue to lose money in the first half of 2021
.
In early June, the Shenzhen Stock Exchange issued an inquiry letter for the 2020 annual report to Innovative Medical, requesting explanations on the company’s provision of estimated liabilities and the reasons and rationality of the impairment of goodwill; on June 18, Innovative Medical issued an inquiry.
The inquiry letter responded to the announcement, and then the Shenzhen Stock Exchange issued a second inquiry letter for the 2020 annual report to Innovative Medical
.
During this period, Innovative Medical announced that the company used its own funds to increase the capital of Futian Hospital by 10 million yuan
.
Concluding remarks
Brokerage analysis pointed out that in the first half of 2021, the pharmaceutical industry is basically gearing up.
The epidemic situation in some countries and regions has rebounded, and the demand for related drugs and testing reagents has increased.
The contribution to the company 's performance may be reflected in the interim report
.
In the second half of the year, the pharmaceutical industry's fundamentally positive trend is expected to continue.
As the low base effect decreases quarter by quarter in 2020, the pharmaceutical industry, especially the leading companies, will have a more prominent performance sustainability advantage
.
The epidemic situation in some countries and regions has rebounded, and the demand for related drugs and testing reagents has increased.
The contribution to the company 's performance may be reflected in the interim report
.
In the second half of the year, the pharmaceutical industry's fundamentally positive trend is expected to continue.
As the low base effect decreases quarter by quarter in 2020, the pharmaceutical industry, especially the leading companies, will have a more prominent performance sustainability advantage
.
Source: Oriental Fortune.
com, Announcement of Listed Companies
com, Announcement of Listed Companies
Medical News, June 25, 2021 is about halfway through, and the performance of listed companies in the first half of the year has gradually surfaced
.
According to statistics, 42 pharmaceutical companies in A-shares have disclosed their performance in the first half of 2021
.
Among them, Kelun Pharmaceutical, Harbin Sanlian, SINBON Pharmaceuticals, and Zuoli Pharmaceuticals are expected to double their net profits.
Daan Gene's net profit will exceed 1.
6 billion yuan.
Harbin Sanlian has the largest increase, with a year-on-year increase of 1856.
54% to 1927.
68%.
; 4 companies are expected to turn losses into profits, Can Sino will usher in the first profit, the current market value of more than 160 billion yuan
.
In addition, 14 companies are expected to lose money, and as many as 11 companies continue to lose money.
Innovative Medical has accumulated losses of nearly 1.
5 billion yuan in the past two years and is expected to continue to lose money in the first half of this year
.
.
According to statistics, 42 pharmaceutical companies in A-shares have disclosed their performance in the first half of 2021
.
Among them, Kelun Pharmaceutical, Harbin Sanlian, SINBON Pharmaceuticals, and Zuoli Pharmaceuticals are expected to double their net profits.
Daan Gene's net profit will exceed 1.
6 billion yuan.
Harbin Sanlian has the largest increase, with a year-on-year increase of 1856.
54% to 1927.
68%.
; 4 companies are expected to turn losses into profits, Can Sino will usher in the first profit, the current market value of more than 160 billion yuan
.
In addition, 14 companies are expected to lose money, and as many as 11 companies continue to lose money.
Innovative Medical has accumulated losses of nearly 1.
5 billion yuan in the past two years and is expected to continue to lose money in the first half of this year
.
A-share pharmaceutical companies that have disclosed their performance forecast for the first half of 2021
Kelun, SINBON.
.
.
11 net profits doubled! This "Hurricane" over 1.
6 billion is too amazing
.
.
11 net profits doubled! This "Hurricane" over 1.
6 billion is too amazing
On the whole, more than 20 pharmaceutical companies reported good news.
Among them, Daan Gene's net profit exceeded 1.
6 billion yuan, and 11 companies including Kelun Pharmaceutical, Harbin Sanlian, Xinbang Pharmaceutical, and Zuoli Pharmaceutical were expected to double their net profits.
The Harbin Sanlian had the largest increase, with a year-on-year increase of 1856.
54% to 1927.
68%
.
Among them, Daan Gene's net profit exceeded 1.
6 billion yuan, and 11 companies including Kelun Pharmaceutical, Harbin Sanlian, Xinbang Pharmaceutical, and Zuoli Pharmaceutical were expected to double their net profits.
The Harbin Sanlian had the largest increase, with a year-on-year increase of 1856.
54% to 1927.
68%
.
Kelun Pharmaceutical: The company's performance in the first quarter of this year has grown rapidly, with net profit increasing by more than 700% year-on-year.
Net profit in the first half of the year is expected to be 400 million to 500 million yuan
.
Regarding the rapid growth of performance, Kelun Pharmaceutical said that on the one hand, with the effective control of the domestic epidemic in the first half of 2021, production and sales gradually recovered, and sales of the company’s traditional infusion, non-infusion products and new products increased year-on-year; on the other hand, Yili Chuanning Affected by the market environment, prices of biological products have resumed rising, and profits have increased year-on-year
.
In addition, the company continued to increase investment in innovation, and R&D expenses increased year-on-year
.
Recently, Kelun Pharmaceutical has received frequent reports.
The KL590586 capsule, a type 1 innovative drug developed by its holding subsidiary Sichuan Kelun Botai Biopharmaceutical, has been notified of clinical trials; Hunan Kelun Pharmaceutical’s linezolid glucose injection has been approved and reviewed.
Won admission tickets for 1 billion injections from China
.
In addition, Kelun Pharmaceutical intends to spin off its holding subsidiary Yili Chuanning Biotechnology to be listed on the Shenzhen Stock Exchange's Growth Enterprise Market
.
On June 22, Kelun Pharmaceutical once again issued two announcements.
Hunan Kelun Pharmaceutical’s erlotinib hydrochloride and Shandong Kelun Pharmaceutical’s iopamidol injection were approved, and the iopamidol injection was Kelun.
The first drug approved to enter the field of diagnostic imaging
.
Net profit in the first half of the year is expected to be 400 million to 500 million yuan
.
Regarding the rapid growth of performance, Kelun Pharmaceutical said that on the one hand, with the effective control of the domestic epidemic in the first half of 2021, production and sales gradually recovered, and sales of the company’s traditional infusion, non-infusion products and new products increased year-on-year; on the other hand, Yili Chuanning Affected by the market environment, prices of biological products have resumed rising, and profits have increased year-on-year
.
In addition, the company continued to increase investment in innovation, and R&D expenses increased year-on-year
.
Recently, Kelun Pharmaceutical has received frequent reports.
The KL590586 capsule, a type 1 innovative drug developed by its holding subsidiary Sichuan Kelun Botai Biopharmaceutical, has been notified of clinical trials; Hunan Kelun Pharmaceutical’s linezolid glucose injection has been approved and reviewed.
Won admission tickets for 1 billion injections from China
.
In addition, Kelun Pharmaceutical intends to spin off its holding subsidiary Yili Chuanning Biotechnology to be listed on the Shenzhen Stock Exchange's Growth Enterprise Market
.
On June 22, Kelun Pharmaceutical once again issued two announcements.
Hunan Kelun Pharmaceutical’s erlotinib hydrochloride and Shandong Kelun Pharmaceutical’s iopamidol injection were approved, and the iopamidol injection was Kelun.
The first drug approved to enter the field of diagnostic imaging
.
SINBON Pharmaceuticals: The net profit for the first half of the year is estimated to be 139 million to 157 million yuan, a year-on-year increase of 290% to 340.
02%, which is close to the full-year level of 2020
.
In this regard, SINBON Pharmaceuticals stated that the impact of the new crown epidemic in 2020 will have a greater impact on the company's operating performance in the first quarter, and it will return to normal in the second quarter.
In the first half of 2021, all business sectors of the company will maintain a continuous growth trend
.
02%, which is close to the full-year level of 2020
.
In this regard, SINBON Pharmaceuticals stated that the impact of the new crown epidemic in 2020 will have a greater impact on the company's operating performance in the first quarter, and it will return to normal in the second quarter.
In the first half of 2021, all business sectors of the company will maintain a continuous growth trend
.
Daan Gene: After making a huge profit of more than 2 billion yuan last year, the company's net profit in the first quarter of this year has exceeded 1 billion yuan.
The growth in the first half of this year is still amazing.
The net profit is expected to be 1.
35 billion to 1.
65 billion yuan, an increase of 73.
41% to 111.
95.
%
.
It is worth mentioning that the net profit in the first half of 2020 exceeded 700 million yuan, a year-on-year increase of 118.
65%; in the first half of 2019, it was only 60.
51 million yuan
.
Daan Gene said that the rapid growth in performance is mainly due to the impact of the new crown virus, and the market has a large demand for new crown virus nucleic acid detection reagents
.
In early June of this year, Daan Gene issued an announcement stating that the company name "Sun Yat-Sen University Daan Gene Co.
, Ltd.
" was changed to "Guangzhou Daan Gene Co.
, Ltd.
" due to a change in the actual controller
.
According to the data, according to the latest business registration information of the controlling shareholder Guangzhou Zhongda Holding Co.
, Ltd.
, its shareholder was changed from "Sun Yat-Sen University" to "Guangzhou Financial Holding Group Co.
, Ltd.
", and the actual controller of the company was changed from "Sun Yat-Sen University" to "Guangzhou City".
People's Government"
.
The growth in the first half of this year is still amazing.
The net profit is expected to be 1.
35 billion to 1.
65 billion yuan, an increase of 73.
41% to 111.
95.
%
.
It is worth mentioning that the net profit in the first half of 2020 exceeded 700 million yuan, a year-on-year increase of 118.
65%; in the first half of 2019, it was only 60.
51 million yuan
.
Daan Gene said that the rapid growth in performance is mainly due to the impact of the new crown virus, and the market has a large demand for new crown virus nucleic acid detection reagents
.
In early June of this year, Daan Gene issued an announcement stating that the company name "Sun Yat-Sen University Daan Gene Co.
, Ltd.
" was changed to "Guangzhou Daan Gene Co.
, Ltd.
" due to a change in the actual controller
.
According to the data, according to the latest business registration information of the controlling shareholder Guangzhou Zhongda Holding Co.
, Ltd.
, its shareholder was changed from "Sun Yat-Sen University" to "Guangzhou Financial Holding Group Co.
, Ltd.
", and the actual controller of the company was changed from "Sun Yat-Sen University" to "Guangzhou City".
People's Government"
.
14 companies lose money! 4 companies turned losses, 100 billion market capitalization pharmaceutical companies will welcome the first profit
According to statistics, four companies, including Cansino and Toujing Life, are expected to turn losses into profits.
Among them, Cansino may make profits for the first time, and its current market value exceeds 160 billion yuan
.
In addition, 14 pharmaceutical companies lost money, while 11 continued to lose money.
Among them, Innovative Medical continued to lose money in the first half of this year after a cumulative loss of nearly 1.
5 billion from 2019 to 2020
.
Among them, Cansino may make profits for the first time, and its current market value exceeds 160 billion yuan
.
In addition, 14 pharmaceutical companies lost money, while 11 continued to lose money.
Among them, Innovative Medical continued to lose money in the first half of this year after a cumulative loss of nearly 1.
5 billion from 2019 to 2020
.
Cansino: In August 2020, Cansino officially listed on the A-share science and technology innovation board.
The company is an innovative vaccine company dedicated to R&D, production and commercialization that meets Chinese and international standards
.
Cansino disclosed the first half of the performance forecast in the first quarter of 2021.
The company expects to turn losses into profits, and this will be the first time Cansino has achieved profitability
.
According to data, from 2016 to 2020, the company is in a state of loss, with a cumulative loss of more than 800 million yuan
.
Kansino stated that the main reason for the turnaround is that the recombinant new coronavirus vaccine (type 5 adenovirus vector) has obtained emergency use authorization from Mexico, Pakistan and other countries and the approval of conditional listing in China, which has positively generated the company's main business income.
Influence
.
Recently, Ecuador’s National Health Regulatory Agency announced that it has approved Cansino’s new crown vaccine for use in Ecuador.
This is the second Chinese new crown vaccine approved for use in Ecuador after Coxing’s new crown vaccine.
In addition, the Malaysian Ministry of Health announced , The Malaysian Drug Control Law Enforcement Group meeting decided to conditionally approve two single-dose vaccines, including China's Cansino vaccine and Johnson & Johnson vaccine for use in Malaysia
.
Currently, Cansino has a market value of more than 160 billion yuan
.
The company is an innovative vaccine company dedicated to R&D, production and commercialization that meets Chinese and international standards
.
Cansino disclosed the first half of the performance forecast in the first quarter of 2021.
The company expects to turn losses into profits, and this will be the first time Cansino has achieved profitability
.
According to data, from 2016 to 2020, the company is in a state of loss, with a cumulative loss of more than 800 million yuan
.
Kansino stated that the main reason for the turnaround is that the recombinant new coronavirus vaccine (type 5 adenovirus vector) has obtained emergency use authorization from Mexico, Pakistan and other countries and the approval of conditional listing in China, which has positively generated the company's main business income.
Influence
.
Recently, Ecuador’s National Health Regulatory Agency announced that it has approved Cansino’s new crown vaccine for use in Ecuador.
This is the second Chinese new crown vaccine approved for use in Ecuador after Coxing’s new crown vaccine.
In addition, the Malaysian Ministry of Health announced , The Malaysian Drug Control Law Enforcement Group meeting decided to conditionally approve two single-dose vaccines, including China's Cansino vaccine and Johnson & Johnson vaccine for use in Malaysia
.
Currently, Cansino has a market value of more than 160 billion yuan
.
Innovative Medical: Innovative Medical’s main business is medical services, and it has three wholly-owned hospital subsidiaries, Jianhua Hospital , Kanghua Hospital and Futian Hospital
.
The company has a cumulative loss of nearly 1.
5 billion yuan from 2019 to 2020, and it is expected to lose 55 million to 45 million yuan in the first half of this year
.
Regarding the decline in performance, Innovative Medical said that in the first quarter of 2021, the net profit loss was 24.
05 million yuan.
The following hospitals did not experience major changes in the operating situation in the second quarter.
The company expects to continue to lose money in the first half of 2021
.
In early June, the Shenzhen Stock Exchange issued an inquiry letter for the 2020 annual report to Innovative Medical, requesting explanations on the company’s provision of estimated liabilities and the reasons and rationality of the impairment of goodwill; on June 18, Innovative Medical issued an inquiry.
The inquiry letter responded to the announcement, and then the Shenzhen Stock Exchange issued a second inquiry letter for the 2020 annual report to Innovative Medical
.
During this period, Innovative Medical announced that the company used its own funds to increase the capital of Futian Hospital by 10 million yuan
.
.
The company has a cumulative loss of nearly 1.
5 billion yuan from 2019 to 2020, and it is expected to lose 55 million to 45 million yuan in the first half of this year
.
Regarding the decline in performance, Innovative Medical said that in the first quarter of 2021, the net profit loss was 24.
05 million yuan.
The following hospitals did not experience major changes in the operating situation in the second quarter.
The company expects to continue to lose money in the first half of 2021
.
In early June, the Shenzhen Stock Exchange issued an inquiry letter for the 2020 annual report to Innovative Medical, requesting explanations on the company’s provision of estimated liabilities and the reasons and rationality of the impairment of goodwill; on June 18, Innovative Medical issued an inquiry.
The inquiry letter responded to the announcement, and then the Shenzhen Stock Exchange issued a second inquiry letter for the 2020 annual report to Innovative Medical
.
During this period, Innovative Medical announced that the company used its own funds to increase the capital of Futian Hospital by 10 million yuan
.
Concluding remarks
Brokerage analysis pointed out that in the first half of 2021, the pharmaceutical industry is basically gearing up.
The epidemic situation in some countries and regions has rebounded, and the demand for related drugs and testing reagents has increased.
The contribution to the company 's performance may be reflected in the interim report
.
In the second half of the year, the pharmaceutical industry's fundamentally positive trend is expected to continue.
As the low base effect decreases quarter by quarter in 2020, the pharmaceutical industry, especially the leading companies, will have a more prominent performance sustainability advantage
.
The epidemic situation in some countries and regions has rebounded, and the demand for related drugs and testing reagents has increased.
The contribution to the company 's performance may be reflected in the interim report
.
In the second half of the year, the pharmaceutical industry's fundamentally positive trend is expected to continue.
As the low base effect decreases quarter by quarter in 2020, the pharmaceutical industry, especially the leading companies, will have a more prominent performance sustainability advantage
.
Source: Oriental Fortune.
com, Announcement of Listed Companies
com, Announcement of Listed Companies
Medical News, June 25, 2021 is about halfway through, and the performance of listed companies in the first half of the year has gradually surfaced
.
According to statistics, 42 pharmaceutical companies in A-shares have disclosed their performance in the first half of 2021
.
Among them, Kelun Pharmaceutical, Harbin Sanlian, SINBON Pharmaceuticals, and Zuoli Pharmaceuticals are expected to double their net profits.
Daan Gene's net profit will exceed 1.
6 billion yuan.
Harbin Sanlian has the largest increase, with a year-on-year increase of 1856.
54% to 1927.
68%.
; 4 companies are expected to turn losses into profits, Can Sino will usher in the first profit, the current market value of more than 160 billion yuan
.
In addition, 14 companies are expected to lose money, and as many as 11 companies continue to lose money.
Innovative Medical has accumulated losses of nearly 1.
5 billion yuan in the past two years and is expected to continue to lose money in the first half of this year
.
.
According to statistics, 42 pharmaceutical companies in A-shares have disclosed their performance in the first half of 2021
.
Among them, Kelun Pharmaceutical, Harbin Sanlian, SINBON Pharmaceuticals, and Zuoli Pharmaceuticals are expected to double their net profits.
Daan Gene's net profit will exceed 1.
6 billion yuan.
Harbin Sanlian has the largest increase, with a year-on-year increase of 1856.
54% to 1927.
68%.
; 4 companies are expected to turn losses into profits, Can Sino will usher in the first profit, the current market value of more than 160 billion yuan
.
In addition, 14 companies are expected to lose money, and as many as 11 companies continue to lose money.
Innovative Medical has accumulated losses of nearly 1.
5 billion yuan in the past two years and is expected to continue to lose money in the first half of this year
.
A-share pharmaceutical companies that have disclosed their performance forecast for the first half of 2021
Kelun, SINBON.
.
.
11 net profits doubled! This "Hurricane" over 1.
6 billion is too amazing
Kelun, SINBON. .
.
11 net profits doubled! This "Hurricane" over 1.
6 billion is too amazing
.
.
11 net profits doubled! This "Hurricane" over 1.
6 billion is too amazing
On the whole, more than 20 pharmaceutical companies reported good news.
Among them, Daan Gene's net profit exceeded 1.
6 billion yuan, and 11 companies including Kelun Pharmaceutical, Harbin Sanlian, Xinbang Pharmaceutical, and Zuoli Pharmaceutical were expected to double their net profits.
The Harbin Sanlian had the largest increase, with a year-on-year increase of 1856.
54% to 1927.
68%
.
Among them, Daan Gene's net profit exceeded 1.
6 billion yuan, and 11 companies including Kelun Pharmaceutical, Harbin Sanlian, Xinbang Pharmaceutical, and Zuoli Pharmaceutical were expected to double their net profits.
The Harbin Sanlian had the largest increase, with a year-on-year increase of 1856.
54% to 1927.
68%
.
Kelun Pharmaceutical: The company's performance in the first quarter of this year has grown rapidly, with net profit increasing by more than 700% year-on-year.
Net profit in the first half of the year is expected to be 400 million to 500 million yuan
.
Regarding the rapid growth of performance, Kelun Pharmaceutical said that on the one hand, with the effective control of the domestic epidemic in the first half of 2021, production and sales gradually recovered, and sales of the company’s traditional infusion, non-infusion products and new products increased year-on-year; on the other hand, Yili Chuanning Affected by the market environment, prices of biological products have resumed rising, and profits have increased year-on-year
.
In addition, the company continued to increase investment in innovation, and R&D expenses increased year-on-year
.
Recently, Kelun Pharmaceutical has received frequent reports.
The KL590586 capsule, a type 1 innovative drug developed by its holding subsidiary Sichuan Kelun Botai Biopharmaceutical, has been notified of clinical trials; Hunan Kelun Pharmaceutical’s linezolid glucose injection has been approved and reviewed.
Won admission tickets for 1 billion injections from China
.
In addition, Kelun Pharmaceutical intends to spin off its holding subsidiary Yili Chuanning Biotechnology to be listed on the Shenzhen Stock Exchange's Growth Enterprise Market
.
On June 22, Kelun Pharmaceutical once again issued two announcements.
Hunan Kelun Pharmaceutical’s erlotinib hydrochloride and Shandong Kelun Pharmaceutical’s iopamidol injection were approved, and the iopamidol injection was Kelun.
The first drug approved to enter the field of diagnostic imaging
.
Venture Venture VentureNet profit in the first half of the year is expected to be 400 million to 500 million yuan
.
Regarding the rapid growth of performance, Kelun Pharmaceutical said that on the one hand, with the effective control of the domestic epidemic in the first half of 2021, production and sales gradually recovered, and sales of the company’s traditional infusion, non-infusion products and new products increased year-on-year; on the other hand, Yili Chuanning Affected by the market environment, prices of biological products have resumed rising, and profits have increased year-on-year
.
In addition, the company continued to increase investment in innovation, and R&D expenses increased year-on-year
.
Recently, Kelun Pharmaceutical has received frequent reports.
The KL590586 capsule, a type 1 innovative drug developed by its holding subsidiary Sichuan Kelun Botai Biopharmaceutical, has been notified of clinical trials; Hunan Kelun Pharmaceutical’s linezolid glucose injection has been approved and reviewed.
Won admission tickets for 1 billion injections from China
.
In addition, Kelun Pharmaceutical intends to spin off its holding subsidiary Yili Chuanning Biotechnology to be listed on the Shenzhen Stock Exchange's Growth Enterprise Market
.
On June 22, Kelun Pharmaceutical once again issued two announcements.
Hunan Kelun Pharmaceutical’s erlotinib hydrochloride and Shandong Kelun Pharmaceutical’s iopamidol injection were approved, and the iopamidol injection was Kelun.
The first drug approved to enter the field of diagnostic imaging
.
SINBON Pharmaceuticals: The net profit for the first half of the year is estimated to be 139 million to 157 million yuan, a year-on-year increase of 290% to 340.
02%, which is close to the full-year level of 2020
.
In this regard, SINBON Pharmaceuticals stated that the impact of the new crown epidemic in 2020 will have a greater impact on the company's operating performance in the first quarter, and it will return to normal in the second quarter.
In the first half of 2021, all business sectors of the company will maintain a continuous growth trend
.
02%, which is close to the full-year level of 2020
.
In this regard, SINBON Pharmaceuticals stated that the impact of the new crown epidemic in 2020 will have a greater impact on the company's operating performance in the first quarter, and it will return to normal in the second quarter.
In the first half of 2021, all business sectors of the company will maintain a continuous growth trend
.
Daan Gene: After making a huge profit of more than 2 billion yuan last year, the company's net profit in the first quarter of this year has exceeded 1 billion yuan.
The growth in the first half of this year is still amazing.
The net profit is expected to be 1.
35 billion to 1.
65 billion yuan, an increase of 73.
41% to 111.
95.
%
.
It is worth mentioning that the net profit in the first half of 2020 exceeded 700 million yuan, a year-on-year increase of 118.
65%; in the first half of 2019, it was only 60.
51 million yuan
.
Daan Gene said that the rapid growth in performance is mainly due to the impact of the new crown virus, and the market has a large demand for new crown virus nucleic acid detection reagents
.
In early June of this year, Daan Gene issued an announcement stating that the company name "Sun Yat-Sen University Daan Gene Co.
, Ltd.
" was changed to "Guangzhou Daan Gene Co.
, Ltd.
" due to a change in the actual controller
.
According to the data, according to the latest business registration information of the controlling shareholder Guangzhou Zhongda Holding Co.
, Ltd.
, its shareholder was changed from "Sun Yat-Sen University" to "Guangzhou Financial Holding Group Co.
, Ltd.
", and the actual controller of the company was changed from "Sun Yat-Sen University" to "Guangzhou City".
People's Government"
.
The growth in the first half of this year is still amazing.
The net profit is expected to be 1.
35 billion to 1.
65 billion yuan, an increase of 73.
41% to 111.
95.
%
.
It is worth mentioning that the net profit in the first half of 2020 exceeded 700 million yuan, a year-on-year increase of 118.
65%; in the first half of 2019, it was only 60.
51 million yuan
.
Daan Gene said that the rapid growth in performance is mainly due to the impact of the new crown virus, and the market has a large demand for new crown virus nucleic acid detection reagents
.
In early June of this year, Daan Gene issued an announcement stating that the company name "Sun Yat-Sen University Daan Gene Co.
, Ltd.
" was changed to "Guangzhou Daan Gene Co.
, Ltd.
" due to a change in the actual controller
.
According to the data, according to the latest business registration information of the controlling shareholder Guangzhou Zhongda Holding Co.
, Ltd.
, its shareholder was changed from "Sun Yat-Sen University" to "Guangzhou Financial Holding Group Co.
, Ltd.
", and the actual controller of the company was changed from "Sun Yat-Sen University" to "Guangzhou City".
People's Government"
.
14 companies lose money! 4 companies turned losses, 100 billion market capitalization pharmaceutical companies will welcome the first profit
14 companies lose money! 4 companies turned losses, 100 billion market capitalization pharmaceutical companies will welcome the first profit According to statistics, four companies, including Cansino and Toujing Life, are expected to turn losses into profits.
Among them, Cansino may make profits for the first time, and its current market value exceeds 160 billion yuan
.
In addition, 14 pharmaceutical companies lost money, while 11 continued to lose money.
Among them, Innovative Medical continued to lose money in the first half of this year after a cumulative loss of nearly 1.
5 billion from 2019 to 2020
.
Among them, Cansino may make profits for the first time, and its current market value exceeds 160 billion yuan
.
In addition, 14 pharmaceutical companies lost money, while 11 continued to lose money.
Among them, Innovative Medical continued to lose money in the first half of this year after a cumulative loss of nearly 1.
5 billion from 2019 to 2020
.
Cansino: In August 2020, Cansino officially listed on the A-share science and technology innovation board.
The company is an innovative vaccine company dedicated to R&D, production and commercialization that meets Chinese and international standards
.
Cansino disclosed the first half of the performance forecast in the first quarter of 2021.
The company expects to turn losses into profits, and this will be the first time Cansino has achieved profitability
.
According to data, from 2016 to 2020, the company is in a state of loss, with a cumulative loss of more than 800 million yuan
.
Kansino stated that the main reason for the turnaround is that the recombinant new coronavirus vaccine (type 5 adenovirus vector) has obtained emergency use authorization from Mexico, Pakistan and other countries and the approval of conditional listing in China, which has positively generated the company's main business income.
Influence
.
Recently, Ecuador’s National Health Regulatory Agency announced that it has approved Cansino’s new crown vaccine for use in Ecuador.
This is the second Chinese new crown vaccine approved for use in Ecuador after Coxing’s new crown vaccine.
In addition, the Malaysian Ministry of Health announced , The Malaysian Drug Control Law Enforcement Group meeting decided to conditionally approve two single-dose vaccines, including China's Cansino vaccine and Johnson & Johnson vaccine for use in Malaysia
.
Currently, Cansino has a market value of more than 160 billion yuan
.
Medicine, medicine, medicineThe company is an innovative vaccine company dedicated to R&D, production and commercialization that meets Chinese and international standards
.
Cansino disclosed the first half of the performance forecast in the first quarter of 2021.
The company expects to turn losses into profits, and this will be the first time Cansino has achieved profitability
.
According to data, from 2016 to 2020, the company is in a state of loss, with a cumulative loss of more than 800 million yuan
.
Kansino stated that the main reason for the turnaround is that the recombinant new coronavirus vaccine (type 5 adenovirus vector) has obtained emergency use authorization from Mexico, Pakistan and other countries and the approval of conditional listing in China, which has positively generated the company's main business income.
Influence
.
Recently, Ecuador’s National Health Regulatory Agency announced that it has approved Cansino’s new crown vaccine for use in Ecuador.
This is the second Chinese new crown vaccine approved for use in Ecuador after Coxing’s new crown vaccine.
In addition, the Malaysian Ministry of Health announced , The Malaysian Drug Control Law Enforcement Group meeting decided to conditionally approve two single-dose vaccines, including China's Cansino vaccine and Johnson & Johnson vaccine for use in Malaysia
.
Currently, Cansino has a market value of more than 160 billion yuan
.
Innovative Medical: Innovative Medical’s main business is medical services, and it has three wholly-owned hospital subsidiaries, Jianhua Hospital , Kanghua Hospital and Futian Hospital
.
The company has a cumulative loss of nearly 1.
5 billion yuan from 2019 to 2020, and it is expected to lose 55 million to 45 million yuan in the first half of this year
.
Regarding the decline in performance, Innovative Medical said that in the first quarter of 2021, the net profit loss was 24.
05 million yuan.
The following hospitals did not experience major changes in the operating situation in the second quarter.
The company expects to continue to lose money in the first half of 2021
.
In early June, the Shenzhen Stock Exchange issued an inquiry letter for the 2020 annual report to Innovative Medical, requesting explanations on the company’s provision of estimated liabilities and the reasons and rationality of the impairment of goodwill; on June 18, Innovative Medical issued an inquiry.
The inquiry letter responded to the announcement, and then the Shenzhen Stock Exchange issued a second inquiry letter for the 2020 annual report to Innovative Medical
.
During this period, Innovative Medical announced that the company used its own funds to increase the capital of Futian Hospital by 10 million yuan
.
Hospital hospital hospital.
The company has a cumulative loss of nearly 1.
5 billion yuan from 2019 to 2020, and it is expected to lose 55 million to 45 million yuan in the first half of this year
.
Regarding the decline in performance, Innovative Medical said that in the first quarter of 2021, the net profit loss was 24.
05 million yuan.
The following hospitals did not experience major changes in the operating situation in the second quarter.
The company expects to continue to lose money in the first half of 2021
.
In early June, the Shenzhen Stock Exchange issued an inquiry letter for the 2020 annual report to Innovative Medical, requesting explanations on the company’s provision of estimated liabilities and the reasons and rationality of the impairment of goodwill; on June 18, Innovative Medical issued an inquiry.
The inquiry letter responded to the announcement, and then the Shenzhen Stock Exchange issued a second inquiry letter for the 2020 annual report to Innovative Medical
.
During this period, Innovative Medical announced that the company used its own funds to increase the capital of Futian Hospital by 10 million yuan
.
Concluding remarks
Brokerage analysis pointed out that in the first half of 2021, the pharmaceutical industry is basically gearing up.
The epidemic situation in some countries and regions has rebounded, and the demand for related drugs and testing reagents has increased.
The contribution to the company 's performance may be reflected in the interim report
.
In the second half of the year, the pharmaceutical industry's fundamentally positive trend is expected to continue.
As the low base effect decreases quarter by quarter in 2020, the pharmaceutical industry, especially the leading companies, will have a more prominent performance sustainability advantage
.
Pharmaceutical Pharmaceutical Pharmaceutical Enterprise Enterprise EnterpriseThe epidemic situation in some countries and regions has rebounded, and the demand for related drugs and testing reagents has increased.
The contribution to the company 's performance may be reflected in the interim report
.
In the second half of the year, the pharmaceutical industry's fundamentally positive trend is expected to continue.
As the low base effect decreases quarter by quarter in 2020, the pharmaceutical industry, especially the leading companies, will have a more prominent performance sustainability advantage
.
Source: Oriental Fortune.
com, Announcement of Listed Companies
com, Announcement of Listed Companies
